Actively Recruiting
Evaluating Lifileucel With Pembrolizumab Versus Pembrolizumab Alone for Untreated Advanced Melanoma in a Phase 3 Randomized Study
Led by Iovance Biotherapeutics, Inc. · Updated on 2026-09-24
670
Participants Needed
82
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of lifileucel combined with pembrolizumab compared to pembrolizumab alone in adults with untreated, unresectable or metastatic melanoma, specifically Stage IIIC, IIID, or IV. This Phase 3, multicenter, randomized, open-label study allows some participants from the pembrolizumab group to switch to lifileucel if their disease progresses. Participants in the lifileucel plus pembrolizumab group first have a tumor sample removed to create the lifileucel treatment. They receive pembrolizumab followed by a lymphodepletion regimen, lifileucel infusion, and IL-2, then continue pembrolizumab every 6 weeks until disease progression. Those in the pembrolizumab alone group receive pembrolizumab every 6 weeks, with an optional crossover to lifileucel if confirmed disease progression occurs. During the study, participants undergo assessments including tumor measurements by RECIST 1.1, organ function tests, and monitoring for adverse events. The main outcomes measured are objective response rate and progression-free survival over 5 years, with additional evaluations of overall survival, duration of response, and safety over up to 7 years. Participants may be followed and evaluated regularly throughout this period.
CONDITIONS
Brief Title
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Research Team
I
Iovance Biotherapeutics https://www.tilvance-301.com
I
Iovance Biotherapeutics Study Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here